PROCEPT BioRobotics to Report Third Quarter Earnings
San Jose-based surgical robotics operators will monitor Q3 results for insight into urology market trends.
Updated on Oct. 12, 2026 in Public Companies
Live Poll
Do you generally trust the quarterly financial reports issued by medical technology companies?
PROCEPT BioRobotics Corporation will report its third quarter 2026 financial results after market close on November 4, 2026. The surgical robotics company manufactures the AQUABEAM and HYDROS Robotic Systems for urological procedures.
Why it matters
The company's performance provides a benchmark for the adoption of robotic surgical technology in the treatment of benign prostatic hyperplasia. This condition currently impacts approximately 40 million men in the United States.
The company will report its third quarter financial results on November 4, 2026, following the release of 250 peer-reviewed publications supporting its primary Aquablation therapy. This system addresses a U.S. market of approximately 40 million men diagnosed with benign prostatic hyperplasia.
The players
PROCEPT BioRobotics Corporation
A San Jose-based surgical robotics company that develops and manufactures technology for urology treatments.
The details
PROCEPT BioRobotics Corporation specializes in robotic systems for the urology sector, specifically Aquablation therapy. Following the release of its financial report on November 4, 2026, the company will host a conference call to discuss its operational and financial performance. Interested parties can access the event through the company's investor relations web portal.
Timeline
October 12, 2026: Company announced its Q3 2026 earnings report date.
November 4, 2026: Company reports Q3 2026 financial results after market close.
November 4, 2026: Conference call begins at 4:30 p.m. Eastern Time.
Market Landscape
This earnings report follows the mandatory schedule dictated by the SEC quarterly reporting cycle for public companies. It serves as a performance check for firms operating in the specialized niche of urological surgical robotics.
Operators should review the company's financial commentary to gauge demand for robotic urology equipment in the current market environment. The call on November 4, 2026, will offer the most direct insight into the company's current operating margins and growth projections.
The takeaway
The upcoming earnings call is a key data point for understanding the adoption trajectory of urology robotics. Operators should monitor the company's commentary on market penetration and clinical adoption rates during the call on November 4, 2026.
What happens next
The conference call will be held on November 4, 2026, and the associated webcast will be available for replay for at least 90 days following the event.
Further reading
For additional context on how organizations manage disclosures, visit the Public Companies section.
More information
To access the financial report and conference call, visit the investor relations web portal.
Live Poll
Do you generally trust the quarterly financial reports issued by medical technology companies?
